Infection control in cystic fibrosis: Cohorting, cross-contamination, and the respiratory therapist

Respiratory Care

Volumn 54, Issue 5, 2009, Pages 641-655

  O'Malley, Catherine A ^a  

^a CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

Bacteria; Cohorting; Cystic fibrosis; Infection control

Indexed keywords

ANTIBIOTIC AGENT;

ACHROMOBACTER XYLOSOXIDANS; ANTIBIOTIC RESISTANCE; BURKHOLDERIA CEPACIA COMPLEX; BURKHOLDERIA CEPACIA INFECTION; CONFERENCE PAPER; DISEASE TRANSMISSION; DISINFECTION; HUMAN; HYGIENE; INFECTION CONTROL; INSTRUMENT STERILIZATION; LUNG FIBROSIS; MEDICAL INSTRUMENTATION; MYCOBACTERIUM; PSEUDOMONAS AERUGINOSA; RESPIRATORY CARE; RESPIRATORY THERAPIST; RESPIRATORY VIRUS; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA;

COHORT STUDIES; CROSS INFECTION; CYSTIC FIBROSIS; HUMANS; INFECTION; INFECTION CONTROL; RISK FACTORS;

EID: 66849138758     PISSN: 00201324     EISSN: None     Source Type: Journal    
DOI: 10.4187/aarc0446     Document Type: Conference Paper

References (118)

1. Rajan S, Saiman L. Pulmonary infections in patients with cystic fibrosis. Semin Respir Infect 2002;17(1):47-56. (Pubitemid 34233391)
2. Cystic Fibrosis Foundation. 2007. Cystic Fibrosis Foundation patient registry 2007. Cystic Fibrosis Foundation, Bethesda, Maryland.
3. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: A common cause of persistent infections. Science 1999;284(5418):1318-1322. (Pubitemid 29289651)
4. Saiman L, Siegel J. Infection control in cystic fibrosis. Clin Microbiol Rev 2004;17(1):57-71. (Pubitemid 38120929)
5. Saiman L, Siegle J; Cystic Fibrosis Foundation. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Infect Control Hosp Epidemiol 2003;24(5 Suppl):S6-S52. (Pubitemid 36617275)
6. Centers for Disease Control. Guidelines for prevention of nosocomial pneumonia. Respir Care 1994;39(12):1191-1236.
7. Health Care Infection Control Practices Advisory Committee (HICPAC). Guidelines for environmental infection control in healthcare facilities. 2001. Centers for Disease Control and Prevention, Atlanta, GA.
8. LiPuma JJ. Update on the Burkholderia nomenclature and resistance. Clinical Microbil Newsletter 2007;29:9,65-69.
9. LiPuma JJ. Update on the Burkholderia cepacia complex. Curr Opin Pulm Med 2005;11(6):528-533.
10. Isles A, Maclusky I, Corey M, Gold R, Prober C, Fleming P, Levison H. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr 1984;104(2):206-210.
11. Tablan O, Martone W, Doershuk C, Stern R, Thomassen J, Klinger D, et al. Colonization of the respiratory tract with Pseudomonas cepacia in cystic fibrosis. Risk factors and outcomes Chest 1987;91(4):527-532.
12. Aris RM, Routh JC, LiPuma JJ, Heath DG, Gilligan PH. Burkholderia cepacia complex in cystic fibrosis patients after lung transplantation: survival linked to genomovar type. Am J Respir Crit Care Med 2001;164(11):2102-2106.
13. Mahenthiralingam E, Vandamme P, Campbell ME, Henry DA, Gravelle AM, Wong LT, et al. Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Burkholderia multivorans. Clin Infect Dis 2001;33(9):1469-1475. (Pubitemid 34246138)
14. Drabick JA, Gracely EJ, Heidecker GJ, LiPuma JJ. Survival of Burkholderia cepacia on environmental surfaces. J Hosp Infect 1996;32(4):267-276.
15. Zuckerman B, Seder D. Infection control practice in cystic fibrosis. Clin Chest Med 2007;381-404. (Pubitemid 46661879)
16. Thomassen MJ, Demko CA, Doershuk CF, Stern R, Klinger JD. Pseudomonas cepacia: decrease in colonization in patients with cystic fibrosis. Am Rev Respir Dis 1986;134(4):669-671.
17. LiPuma JJ, Dasen SE, Nielson DW, Stern RC, Stull TL. Person to person transmission of Pseudomonas cepacia between patients with cystic fibrosis. Lancet 1990;336(8723):1094-1096.
18. Pegues DA, Carson LA, Tablan OC, FitzSimmons SC, Roman SB, Miller JM, Jarvis WR; Summer Camp Study Group. Acquisition of Pseudomonas cepacia at summer camps for patients with cystic fibrosis. J Pediatr 1994;124(5 Pt 1):694-702.
19. Johnson WM, Tyler SD, Rozee KR. Linkage analysis of geographical and clinical clusters in Pseudomonas cepacia infections by multilocus enzyme electrophoresis and ribotyping. J Clin Microbiol 1994;32(4):924-930
20. Govan JR, Brown PH, Maddison J, Doherty C, Nelson JW, Dodd M, et al. Evidence of transmission of Pseudomonas cepacia by social contact in cystic fibrosis. Lancet 1993;342(8862):15-19.
21. Jones AM, Dodd ME, Webb AK. Burkholderia cepacia: current clinical issues, environmental controversies and ethical dilemmas. Eur Respir J 2001;17(2):295-301.
22. Pegues DA, Schidlow DV, Tablan OC, Carson LA, Clark NC, Jarvis WR. Possible nosocomial transmission of Pseudomonas cepacia in patients with cystic fibrosis. Arch Pediatr Adolesc Med 1994;148(8):805-812.
23. Holmes A, Nolan R, Taylor R, Finley R, Riley M, Jiang RZ, et al. An epidemic of Burkholderia cepacia transmitted between patients with and without cystic fibrosis. J Infect Dis 1999;179(5):1197-1205.
24. Reboli AC, Koshinski R, Arias K, Marks-Austin K, Stieritz D, Stull TL. An outbreak of Burkholderia cepacia lower respiratory tract infection associated with contaminated albuterol nebulization solution. Infect Control Hosp Epidemiol 1996;17(11):741-743.
25. Nelson JW, Doherty CJ, Brown PH, Greening AP, Kaufmann ME, Govan JR. Pseudomonas cepacia in inpatients with cystic fibrosis. Lancet 1991;338(8781):1525.
26. Chen JS, Witzmann K, Spilker T, Fink R, Lipuma JJ. Endemicity and inter-city spread of Burkholderia cepacia genomovar III in cystic fibrosis. J Pediatr 2001;139(5):643-649.
27. Biddick R, Spilker T, Martin A, LiPuma JJ. Evidence of transmission of Burkholderia cepacia, Burkholderia multivorans, and Burkholderia dolosa among person with cystic fibrosis FEMS Microbiol Lett 2003;228(1):57-62.
28. Vermis K, Coenye T, LiPuma JJ, Mahenthiralingam E, Nelis HJ, Vandamme P. Proposal to accommodate Burkholderia cepacia genomovar VI as Burkholderia dolosa sp. nov. Int J Syst Evol Microbiol 2004;54(3):689-691.
29. Kalish LA, Waltz DA, Dovey M, Potter-Bynoe G, McAdam AJ, LiPuma JJ, et al. Impact of Burkholderia dolosa on lung function and survival in cystic fibrosis. Am J Respir Crit Care Med 2006;173(4):421-425.
30. Centers for Disease Control. Pseudomonas cepacia at summer camps for persons with cystic fibrosis. Morb Mortal Wkly Rep 1993;42:456-459.
31. Bernhardt SA, Spilker T, Coffey T, LiPuma JJ. Burkholderia cepacia complex in cystic fibrosis: frequency of strain replacement during chronic infection. Clin Infect Dis 2003;37(6):780-785.
32. Fung SK, Dick H, Devlin H, Tullis E. Transmissibility and infection control implications of Burkholderia cepacia in cystic fibrosis. Can Infect Dis J 1998;9:177-182.
33. Paul ML, Pegler MA, Benn RA. Molecular epidemiology of Burkholderia cepacia in two Australian cystic fibrosis centres. J Hosp Infect 1998;38(1):19-26.
34. Döring G, Jansen S, Noll H, Grupp H, Frank F, Botzenhart K, et al. Distribution of Pseudomonas aeruginosa and Burkholderia cepacia in a hospital ward. Pediatr Pulmonol 1996;21(2):90-100.
35. Römling U, Wingender J, Müller H, Tümmler B. A major Pseudomonas aeruginosa clone common to patients and aquatic habitats. Appl Environ Microbiol 1994;60(6):1734-1738.
36. Zimakoff J, Høiby N, Rosendal K, Guilbert JP. Epidemiology of Pseudomonas aeruginosa infection and the role of contamination of the environment in a cystic fibrosis clinic. J Hosp Infect 1983;4(1):31-40.
37. Speert DP, Campbell ME. Hospital epidemiology of Pseudomonas aeruginosa from patients with cystic fibrosis. J Hosp Infect 1987;9(1):11-21.
38. Mahenthiralingham EM, Campbel ME, Foster J, Lam JS, Speert DP. Random amplified polymorphic DNA typing of Pseudomonas aeruginosa isolates recovered from patients with cystic fibrosis. J Clin Microbiol 1996;34(12):1129-1135.
39. Ojeniyi B, Petersen US, Hoiby N. Comparison of genome fingerprinting with conventional typing methods used on Pseudomonas aeruginosa isolates from cystic fibrosis patients. APMIS 1993;101(2):168-175.
40. Römling U, Fiedler B, Bosshammer J, Grothues D, Greipel J, von der Hardt H, Tümmler B. Epidemiology of chronic Pseudomonas aeruginosa infections in cystic fibrosis. J Infect Dis 1994;170(6):1616-1621.
41. Speert DP, Campbell ME, Henry DA, Milner R, Taha F, Gravelle A, et al. Epidemiology of Pseudomonas aeruginosa in cystic fibrosis in British Columbia, Canada. Am J Respir Crit Care Med 2002;166(7):988-993.
42. Bosshammer J, Fiedler B, Gudowius P, von der Hardt H, Römling U, Tümmler B. Comparative hygienic surveillance of contamination with pseudomonads in a cystic fibrosis ward over a 4-year period. J Hosp Infect 1995;31(4):261-274. (Pubitemid 26015721)
43. Wolz C, Kiosz G, Ogle JW, Vasil ML, Schaad U, Botzenhart K, Doring G. Pseudomonas aeruginosa cross-colonization and persistence in patients with cystic fibrosis. Use of a DNA probe. Epidemiol Infect 1989;102(2):205-214.
44. Grothues D, Koopman U, von der Hardt H, Tümmler B. Genome fingerprinting of Pseudomonas aeruginosa indicates colonization of cystic fibrosis siblings with closely related strains. J Clin Microbiol 1988;26(10):1973-1977.
45. Ojeniyi B, Frederiksen B, Hoiby N. Pseudomonas aeruginosa cross-infection among patients with cystic fibrosis during a winter camp. Pediatr Pulmonol 2000;29(3):177-181.
46. Fluge O, Ojeniyi B, Hoiby N, Digranes A, Ciofu O, Hunstad E, et al. Typing of Pseudomonas aeruginosa strains in Norwegian cystic fibrosis patients. Clin Microbiol Infect 2001;7:238-243.
47. McCallum SJ, Corkhill J, GallagerM,Ledson MJ, Hart CA, Walshaw MJ. Superinfection with a transmissible strain of Pseudomonas aeruginosa in adults with cystic fibrosis chronically colonised by P. aeruginosa. Lancet 2001;358(9281):558-560. (Pubitemid 32772735)
48. Cheng K, Smith RL, Govan JR, Doherty C, Winstanley C, Denning N, et al. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet 1996;348(9028):639-642.
49. Jones AM, Govan JR, Doherty CJ, Dodd ME, Isalska BJ, Stanbridge TN, Webb AK. Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic. Lancet 2001;358(9281):557-558.
50. Frederiksen B, Koch C, Høiby N. Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995). Pediatr Pulmonol 1999;28(3):159-166.
51. Høiby N, Pedersen SS. Estimated risk of cross infection with Pseudomonas aeruginosa in Danish cystic fibrosis patients. Acta Paediatr Scand 1989;78(3):395-404.
52. Pedersen SS, Jensen T, Høiby N, Koch C, Flensborg EW. Management of Pseudomonas aeruginosa lung infection in Danish cystic fibrosis patients. Acta Paediatr Scand 1987;76(6):955-961.
53. Pedersen SS, Koch C, Høiby N, Rosendal K. An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre. J Antimicrob Chemother 1986;17(4):505-516.
54. Nixon GM, Armstrong DS, Carzino R, Carlin JB, Olinsky J, Robertson CF, Grimwood K. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 2001;138(5):699-704.
55. Armstrong DS, Nixon GM, Carzino R, Bigham A, Carlin JB, Robins-Browne RM, et al. Detection of a widespread clone of Pseudomonas aeruginosa in a pediatric cystic fibrosis clinic. Am J Respir Crit Care Med 2002;166(7):983-987.
56. Farrell MJ, Shen G, Splaingard M, Colby CE, Laxoya A, Kosorok MR, et al. Acquisition of Pseudomonas aeruginosa in children with cystic fibrosis. Pediatrics 1997;100:E2.
57. Speert DP, Lawton D, Damm S. Communicability of Pseudomonas aeruginosa in a cystic fibrosis summer camp. J Pediatr 1982;101(2):227-228.
58. Anderson DH. Therapy and prognosis of fibrocystic disease of the pancreas. Pediatrics 1949;1949:406-417.
59. Cystic Fibrosis Foundation patient registry, 2001. Cystic Fibrosis Foundation, Bethesda, Maryland.
60. Glikman D, Siegle JD, David MZ, Okoro NM, Boyle-Vavra S, Dowell ML, Dawn RS. Complex molecular epidemiology of MRSA isolate from children with CF in the era of community-asociated MRSA. Chest 2008;133(6):1381-1387.
61. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007;298(15):1763- 1771.
62. Purcell K, Fergie J. Epidemic of community-acquired methicillin-resistant Staphylococcus aureus infections: a 14-year study at Driscoll Children's Hospital. Arch Pediatr Adolesc Med 2005;159(10):980-985.
63. Moran GJ, Krishnadasan A, Gorwitz RJ, Foshei GE, McDougal LK, Carey RB, Talan DA. Methicilin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006;355(7):666-674.
64. Creech CB II, Kernodle DS, Alsentzer A, Wilson C, Edwards KM. Increasing rates of nasal carriage of methicillin-resistant Staphylococcus aureus in healthy children. Pediatr Infect Dis J 2005;24(7):617-621.
65. Vandenesch F, Naimi T, Enright MC, Lina G, Nimmo GR, Heffernan H, et al. Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis 2003;9(8):978-984.
66. Naimi TS, LeDell KH, Como-Sabetti K, Borchardt SM, Boxrud DJ, Etienne J, et al. Comparison of community-and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003;290(22):2976-2984.
67. Diep BA, Gill SR, Chang RF, Phan TH, Chen JH, Davidson MG, et al. Complete genome sequence of USA 300: an epidemic clone of community-acquired methicillin-resistant Staphylococcus aureus. Lancet 2006;367(9512):731-739. (Pubitemid 43326291)
68. Baba T, Takeuchi F, Kuroda M, Yuzawa H, Aoki K, Oguchi A, et al. Genome and virulence determinants of high virulence community-acquired MRSA. Lancet 2002;359(9320):1819-1827. (Pubitemid 34607058)
69. Crawford SE, Boyle-Vavra S, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus. In: Scheld WM, Hooper DC, Hughes JM, eds. Emerging infections 7. Washington DC: ASM press; 2007: 153-179.
70. Francis JS, Doherty MC, Lopatin U, Johnston CP, Sinha G, Ross T, et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 2005;40(1):100-107.
71. Adem PV, Montgomery CP, Husain AN, Koogler TK, Arangelovich V, Humilier M, et al. Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children.NEngl J med. 2005;353(12):1245-1251.
72. Elizur A, Orschein RC, Ferkol TW, Atkinson JJ, Dunne WM, Buller RS, et al. Panton-Valentine leukocidin-positive methicillin-resistant Staphylococcus aureus lung infections in patients with cystic fibrosis. Chest 2007;131(6):1718-1725.
73. Givney R, Vickery A, Holliday A, Pegler M, Benn R. Methicillin-resistant Staphylococcus aureus in a cystic fibrosis unit. J Infect 1997;35(1):27-36.
74. Garner JS, for The Hospital Infection Control Practices Advisory Committee. Guideline for isolation precautions in hospitals. Infect Control Hosp Epidemiol 1996;17(1):53-80.
75. Graff GR, Burns JL. Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis. Chest 2002;121(6):1754-1760.
76. Davies JC, Rubin BK. Emerging and unusual gram-negative infections in cystic fibrosis. Semin Respir Crit Care Med 2007;28(3):312-321. (Pubitemid 46982062)
77. Denton M, Todd NJ, Kerr KG, Hawkey PM, Littlewood JM. Molecular epidemiology of Stenotrophomonas maltophilia isolated from clinical specimens from patients with cystic fibrosis and associated environmental samples. J Clin Microbiol 1998;36(7):1953-1958.
78. Vu-Thien H, Moissenet D, Valcin M, Dulot C, Tournier G, Garbarg-Chenon A. Molecular epidemiology of Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans in a cystic fibrosis center Eur J Clin Microbiol Infect Dis 1996;15(11):876-879.
79. Gómez-Cerezo J, Suárez I, Ríos JJ, Peña P, García de Miguel MJ, de José M, et al. Achromobacter xylosoxidans bacteremia: a10-year analysis of 54 cases. Eur J Clin Microbiol Infect Dis 2003;22(6):360-363.
80. Dunne WM Jr, Maisch S. Epidemiological investigation of infections due to Alcaligenes species in children and patients with cystic fibrosis: use of repetitive-element-sequence polymerase chain reaction. Clin Infect Dis 1995;20(4):836-841.
81. Fabbri A, Tacchella A, Manno G, Viscoli C, Gargani GF. Emerging microorganisms in cystic fibrosis. Chemoterapia 1987;6(1):32-37. (Pubitemid 17035916)
82. Krzewinski JW, Nguyen CD, Foster JM, Burns JL. Use of random amplified polymorphic DNA polymerase chain reaction to determine the epidemiology of Stenotrophomonas maltophilia and Achromobacter (Alcaligenes) xylosoxidans from patients with cystic fibrosis. J Clin Microbiol 2001;39(10):3597-3602.
83. Valdezate S, Vindel A, Maiz L, Baquero F, Escobar H, Cantón R. Persistence and variability of Stenotrophomonas maltophilia in cystic fibrosis patients, Madrid, 1991-1998. Emerg Infect Dis 2001;7(1):113-121.
84. Oliver KN, Weber DJ, Wallace RJ Jr, Faiz AR, Lee JH, Zhang Y, et al. Nontuberculosis mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003;167(6):828-834.
85. Cullen AR, Cannon CL, Mark EJ, Colin AA. Mycobacterium abscessus infection in cystic fibrosis. Am J Respir Crit Care Med 2000;161(2 Pt 1):641-645.
86. Esther CR Jr. Nontuberculous mycobacterium abscessus infection in young children with cystic fibrosis. Pediatr Pulmonol 2005;40(1):39-44. (Pubitemid 40917906)
87. Griffith DE, Girard WM, Wallace RJ Jr. Clinical features of pulmonary disease caused by rapidly growing mycobacteria: an analysis of 154 patients. Am Rev Respir Dis 1993;147(5):1271-1278. (Pubitemid 23149890)
88. Torrens JK, Dawkins P, Conway SP, Moya E. Non-tuberculosis mycobacteria in cystic fibrosis. Thorax 1998;53(3):182-185.
89. Mussaffi H, Rivlin J, Shalit I, Ephros M, Blau H. Nontuberculosis mycobacteria in cystic fibrosis associated with allergic bronchopulmonary aspergillosis and steroid therapy. The Eur Respir J 2005;25(2):324-328. (Pubitemid 40246534)
90. Bargon J, Dauletbaev N, Köhler B, Wolf M, Posselt HG, Wagner TO. Prophylactic antibiotic therapy is associated with an increased prevalence of Aspergillus colonization in adult cystic fibrosis patients. Respir Med 1999;93(11):835-838.
91. Abman SH, Ogle JW, Butler-Simon N, Rumack CM, Accurso FJ. Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J Pediatr 1988;113(5):826-830. (Pubitemid 18272572)
92. Armstrong D, Grimwood K, Carlin JB, Carzino R, Hull J, Olinsky A, Phelan PD. Severe viral respiratory infections in infants with cystic fibrosis. Pulmonol 1998;26(6):371-379. (Pubitemid 29024978)
93. Hiatt PW, Grace SC, Kozinetz CA, Raboudi SH, Treece DJ, Taber LH, Piedra PA. Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis. Pediatrics 1999;103(3):619-626. (Pubitemid 29274510)
94. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics 1998;102:1211-1216.
95. Giebels K, Marcotte JE, Podoba J, Rousseau C, Denis MH, Fauvel V, Laberge S. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis. Pediatr Pulmonol 2008;43(2):169-174. (Pubitemid 351273044)
96. Jarvis WR. Handwashing-the Semmelweis lesson forgotten? Lancet 1994;344(8933):1311-1312.
97. Albert RK, Condie F. Hand-washing patterns in medical intensive-care unit. N Engl J Med 1981;304(24):1465-1466. (Pubitemid 11122483)
98. Graham M. Frequency and duration of handwashing in an intensive care unit. Am J Infect Control 1990;18(2):77-81. (Pubitemid 20271261)
99. Pittet D, Mourouga P, Perneger TV, and members of the Infection Control Program. Compliance with handwashing and hand antisepsis in health care settings. Ann Intern Med 1999;130:126-130.
100. Kretzer EK, Larson EL. Behavioral interventions to improve infection control practices. Am J Infect Control 1998;26(3):245-1223 (Pubitemid 28287463)
101. Pittet D, Hugonnet S, Harbarth S, Mourouga P, Sauvan V, Touveneau S, et al. Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Lancet 2000;356(9238):1307-1312.
102. Karapinar M, Gönül SA. Effects of sodium bicarbonate, vinegar, acetic and citric acids on growth and survival of Yersinia enterocolitica. Int J Food Microbiol 1992;16(4):343-347.
103. Rutala WA, Barbee SL, Aguiar NC, Sobsey MD, Weber DJ. Antimicobial activity of home disinfectants and natural products against potential human pathogens. Infect Control Hosp Epidemiol 2000;21(1):33-38.
104. Mangram A, Jarvis WR. Nosocomial Burkholderia cepacia outbreaks and pseudo-outbreaks. Infect Control Hosp Epidemiol 1996;17:718-720.
105. Hutchinson GR, Parker S, Pryor JA, Duncan-Skingle F, Hoffman PN, Hodson ME, et al. Home-use nebulizers: a potential primary source of Burkholderia cepacia and other colistin-resistant, gram-negative bacteria in patients with cystic fibrosis. J Clin Microbiol 1996;34(3):584-587. Erratum in: J Clin Microbiol 1996;34(5):1601.
106. Pitchford KC, Corey M, Highsmith AK, Perlman R, Bannatyne R, Gold R, et al. Pseudomonas species contamination of cystic fibrosis patients' home inhalation equipment. J Pediatr 1987;111(2):212-216.
107. Rosenfeld M, Joy P, Nguyen CD, Krzewinkski JW, Burns JL. Cleaning home nebulizers used by patients with cystic fibrosis: is rinsing with tap water enough? J Hosp Infect 2001;49(3):229-230.
108. Hamill RJ, Houston ED, Georghiou PR, Wright CE, Koza MA, Cadle RM, et al. An outbreak of Burkholderia (formerly Pseudomonas) cepacia respiratory tract colonization and infection associated with nebulized albuterol therapy. Ann Intern Med 1995;122(10):762-766.
109. Sanders CV Jr, Luby JP, Johanson WG Jr, Barnett JA, Sanford JP. Serratia marcescens infections from inhalation therapy medications: nosocomial outbreak. Ann Intern Med 1970;73(1):15-21.
110. Ramsey AH, Skonieczny P, Coolidge DT, Kurzynski TA, Proctor ME, Davis JP. Burkholderia cepacia lower respiratory tract infection associated with exposure to a respiratory therapist. Infect Control Hosp Epidemiol 2001;22(7):423-426.
111. Vassal S, Taamma R, Marty N, Sardet A, d'athis P, Brémont F, et al. Microbiologic contamination study of nebulizers after aerosol therapy in patients with cystic fibrosis. Am J Infect Control 2000;28(5):347-351.
112. Muscarella L. Contribution of tap water and environmental surfaces to nosocomial transmission of antibiotic-resistant Pseudomonas aeruginosa. Infect Control Hosp Epidemiol 2004;25(4):342-345. (Pubitemid 38524912)
113. Denton M, Rajgopal A, Mooney L, Qureshi A, Kerr KG, Keer V, Peckham DG, Conway SP. Stenotrophomonas maltophilia contamination of nebulizers used to deliver aerosolized therapy to inpatients with cystic fibrosis. J Hosp Infect 2003;55(3):180-183.
114. O'Malley C, VandenBranden S, Xiaotian Z, Polito A, McColley S. A day in the life of a nebulizer: surveillance for bacterial growth in nebulizer equipment of children with cystic fibrosis in the hospital setting. Respir Care 2007;52(3):258-262.
115. Cobben NA, Drent M, Jonkers M, Wouters EFM, Vaneechoutte M, Stobberingh EE. Outbreak of severe Pseudomonas aeruginosa respiratory infections due to contaminated nebulizers. J Hosp Infect 1996;33(1):63-70.
116. Cohen HA, Cohen Z, Pomeranz AS, Czitron B, Kahan E. Bacterial contamination of spacer devices used by asthmatic children. J Asthma 2005;42(3):169-172. (Pubitemid 40776960)
117. Monaghan Medical Corporation. Levalbuterol aerosol delivery with a nonelectrostatic versus a nonconducting valved holding chamber. http://www.monaghanmed.com/clinical-library/levalbuterolaerosol-delivery- nonelectrostatic-versus-nonconducting-valvedholding. Accessed March 20, 2009.
118. Moser C, Høiby N. How relatively simple initiatives have improved the prognosis for people with CF in Denmark. http://www.rileyhospital.org/ parents-and-patients/programs-and-services/cfinfection-prevention.jsp. Indianapolis, In: Riley Hospital for Children. Accessed March 19, 2009.